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FIVE groups of ten female guinea-pigs were passively
sensitized against ovalbumin (OA) (n--9) or control
guinea-pig serum (n 1). 24 h later, they received mepyr-
amine (0.5 mg/kg, i.p.) and 30 min later inhaled aerosols
of: (A) OA (2% in 0.9% saline, 8 rain, n 4/9); (B) saline
(40min, n=419); (C) LPS (40min, Escherichia coil
0111:B4, 150 ng/kg in PBS, n 1/9); and (D) the control
animal was treated as in (C) (n 1). Their tracheas were
cannulated under pentobarbital anaesthesia and bronchial
alveolar lavage (BAL) was performed with 2 x 5 ml PBS
containing BSA (1%) (n 1 group), or BSA (1%) and
aprotinin (1000 KIU/ml) (n 4 groups), at 30, 60, 90 or
120 min post-inhalations. BAL fluids recovered were cen-
trifuged, the supernatants recovered and frozen until as-
sayed for tumour necrosis factor- (TNF-), interleukin-1
(IL-1) and interleukin-6 (IL-6). No TNF- could be de-
tected unless aprotinin was present in the lavaging solu-
tion. BAL fluid from OA-sensitized and control animals
that had inhaled LPS contained high levels ofTNF- that
peaked at 90 rain. BAL fluid from OA sensitized animals
that inhaled OA aerosols contained no detectable TNF-ff
at 30 rain, but it was found in increasing amounts at 60,
90 and 120 rain; TNF- was not detected in fluid from any
of the animals that inhaled saline. As BAL fluids were
toxic to the cells used in the assays, neither IL-1 nor IL-6
could be measured. We conclude that the monokine TNF-
is released into BAL fluid following anaphylactic chal-
lenge of passively sensitized guinea-pigs. The presence of
the antiprotease, aprotinin, in the lavaging solution is
essential for the detection and measurement ofTNF- in
BAL fluid.
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Cytokine mediated interactions among macro-
phages, lymphocytes and eosinophils appear to be
involved in the pathogenesis of the eosinophilia and
airways’ inflammation that characterize asthma.
>4
Thus, tumour necrosis factor alpha (TNF-0) and
granulocyte-macrophage colony-stimulating factor
(GM-CSF), given parenterally, induce the accumu-
lation of eosinophils in the airways of normal
guinea-pigs. Also, TNF-cz is released from
sensitized lung tissue following IgE receptor
triggering,
6 and it contributes to mast cell de-
pendent recruitment of leukocytes during IgE
dependent cutaneous late phase reactions. Alveolar
macrophages isolated from bronchial alveolar
lavage (BAL) fluid from allergen challenged
patients undergoing a late asthmatic response
secrete greater amounts ofTNF- and interleukin-6
(IL-6) than macrophages isolated from BAL fluid
of patients who develop no response or only an
early response to allergen challenge. However,
Gosset et al. were unable to detect TNF-0 in BAL
fluid from asthmatic patients challenged with
antigen inhalation. By contrast, Broide et al.
9
showed that levels of several cytokines, including
TNF-, IL-1 and IL-6, were significantly elevated
in BAL fluid from patients with symptomatic
asthma compared to asymptomatic asthmatic
controls. We used guinea-pigs passively sensitized
to ovalbumin (OA), and determined whether the
cytokines TNF-z, interleukin-1 (IL-1) and inter-
leukin-6 (IL-6) could be detected in BAL fluid
immediately after challenge with an aerosol of OA.
Guinea-pigs passively sensitized to OA and to inert
serum that inhaled LPS served as positive controls
for TNF-cz release.
Methods
Animals: Five groups of ten female Hartley strain
guinea-pigs, SPF quality, weight range 320-400 g,
obtained from Charles River, St Constant,
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Qu4bec were housed in laminar flow units
(BiocleanTM, Hazleton, MD) on grids in cages
suspended over trays of rock salt. They were fed
normal guinea-pig chow supplemented with apples
and allowed water ad libitum. They were monitored
for at least one week after being shipped to ensure
that they were in good health. They weighed
350--450 g at experiment.
Experiments: In each of the five groups of ten
guinea-pigs, nine were passively sensitized to OA
with guinea-pig hyperimmune serum (anti-OA
antibody titre 1:5200, by ELISA; 0.2 ml, i.p.),
and one animal received control guinea-pig serum
(0.2 ml, i.p.). One day later, all animals received
mepyramine (0.5 mg/kg, i.p.) and 30 rain later, the
nine guinea-pigs that had received hyperimmune
serum inhaled aerosols (Vix AcornTM nebulizer,
compressed air at 10 psi) of: (A) OA (2% in 0.9%
saline, up to 8 min, n 4/9); (B) 0.9% saline (as for
(A) n 4/9); (C) LPS (E. coli 0111:B4, 150 ng/ml
in PBS, 40 min, n 1/9; and (D) the guinea-pig
that had received control serum was treated as in
(C). At 30, 60, 90 and 120 min after challenge with
OA or LPS, the groups of ten animals were
anaesthetized (pentobarbital, 40-50mg/kg, i.p.),
their tracheas cannulated (PE240) and BAL
performed.
Bronchial alveolar lavage: One group of guinea-pigs’
lungs was lavaged with 2 x 5 ml PBS containing
BSA (1%); the other four groups were lavaged with
2 x 5 ml PBS containing BSA (1%, to maintain
viability of any cells recovered) and aprotinin
(1000 KIU/ml, to inhibit protease activity8). BAL
fluids recovered were centrifuged (2000 rpm, 5 rain)
and the supernatant removed and immediately
frozen at -20C until assay.
Cytokine measurements: All assays were performed in
triplicate. Levels of TNF- were measured by the
specific ability of this cytokine to exert cytotoxicity
against the L929 fibroblast cell line.
1 Briefly, L929
cells (105) in 100 #1 of complete medium (RPMI
1640, 10% FBS, 1% penicillin-streptomycin) and
actinomycin D (1.0/il/well) were added to serial
dilutions of BAL fluids and incubated for 18 h
(37C, 5% CO2). Then, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolinium bromide (MTT, 25
was added to each well. After further incubation
(4 h), acidified isopropanol was added and optical
densities read at 570 nm. Concentrations of TNF-
in the lavage fluids were calculated using probit
analysis from a standard curve prepared using
human recombinant TNF-.
IL-6 was measured as described recently.
11
Briefly, B9 hybridoma (105 cells/well) was incubated
in fortified RPMI 1640 medium, in the presence of
serial dilutions of BAL fluid. Growth stimulation
was assessed by the MTT procedure described
above. IL-6 levels were derived from a standard
curve prepared with human rIL-6.
IL-1 was measured via the ability of samples of
BAL fluid to support the concanavalin A driven
growth of D10.G4.1 cells. 12 Cells (4 x 105) were
suspended in complete medium containing con-
canavalinA (2.5 #g/ml) with serial dilutions ofBAL
fluid. After incubation (72h, 37C, 5% COg),
growth was assessed by the MTT procedure. A
standard curve was prepared using human re-
combinant IL-1.
Guinea-pig sera" On day 0, guinea-pigs were given
OA (20 mg/kg, i.p.); 21 days later, they inhaled OA
aerosols (2% in saline, mepyramine, 0.5 mg/kg, i.p.,
30 min beforehand) for up to 8 min, on 8
consecutive days. On day 35, they were anaesthe-
tized (pentobarbital, 50mg/kg, i.p.) and blood
collected into plain glass tubes via cardiac puncture.
Tubes were centrifuged and stored at4C overnight
to allow the clot to form and retract. Serum was
collected, pooled and stored at -20C until use.
Anti-OA antibody titres, as total IgG, were
estimated via ELISA. Control sera were prepared
similarly except animals received only vehicle on
day 0, and inhaled only saline aerosols. No anti-OA
antibodies could be detected in control sera.
Reagents and chemicals" Actinomycin D, aprotinin,
concanavalin A, 3-(4,5-dimethylthiazol-2-yl)-di-
phenyltetrazolinium bromide (MTT), chicken egg
albumin (ovalbumin, Grade V) and LPS (E. coli
0111 :B4) (Sigma, St Louis, MO), penicillin-
streptomycin mixture and RPMI 1640 medium
(Gibco, Grand Island, NY) FBS (PA Biologicals,
Sydney, Australia), recombinant human TNF-a and
human recombinant IL-1, (Amersham Canada Ltd,
Oakville, Ontario), rabbit anti-human TNF- and
pre-immune serum (Olympus Corp., New York,
NY), and human recombinant IL-6 (British
Biotechnology, Oxford, UK).
Statistical analyses" Data were expressed as mean q-
S.E.M. Differences among the groups were
examined using Student’s t-test. Differences were
assumed significant at the 5% level.
Results
TNF-: In the absence of aprotinin, TNF- could
not be detected in BAL fluids obtained at 60 min
post-challenge whether guinea-pigs had inhaled
OA saline or LPS (positive controls) aerosols.
However, if animals’ lungs were lavaged with
fluid containing the antiprotease, aprotinin
(1000 KIU/ml), significant amounts of TNF-0 were
detected (Table 1, Fig. 1). In the group challenged
with OA aerosol, TNF- was not detectable in BAL
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Table 1. Amounts of TNF- detected in bronchial alveolar
lavage (BAL) fluids, aprotinin (1000 KIU/ml) present in the
lavaging solution. Four groups of ten guinea-pigs were used. In
each group, nine were passively sensitized with anti-ovalbumin
(OA) serum, and one received control serum (CON). 24 h later,
they received mepyramine (0.5 mg/kg, i.p.) and 30min later
they inhaled aerosols of OA (2% in saline) (OA/OA, n 4),
saline (OA/SAL, n 4), or LPS (OA/LPS, n 1) and control
serum treated animals inhaled LPS (CON/LPS, n 1). 30, 60,
90 and 120 min post-challenge, animals were anaesthetized and
bronchial alveolar lavage performed. Each number is the
mean + SEM
Time (min) post challenge
Treatment 30 60 90 120
OA/OA ND 6 _+ 3 18 _+ 3 26 _+ 6
OA/SAL ND ND ND ND
OA/LPS 8 _+ 3 12 8 63 -I- 15 40 _+ 10
CON/LPS 9 _+ 4 15 _+ 9 56 _+ 6 36 _+ 13
ND None detected.
fluid collected 30 min post-challenge, but increasing
amounts of TNF- were detected at 60, 90 and
120 min post-challenge and were correlated posi-
tively with time BAL fluid was collected post-
challenge. By contrast, TNF-0 was not detected in
BAL fluid from animals challenged with only saline.
However, TNF- was detected in BAL fluid from
both positive controls, the passively sensitized and
control serum treated animals that had inhaled LPS
aerosol (Table 1, Fig. 1). The cytotoxicity of this
TNF-0 was prevented if the BAL fluid, rabbit









TIME LAVAGE PERFORMED POST CHALLENGE (min)
FIG. 1. Amounts of TNF- detected in bronchial alveolar lavage (BAL)
fluid at 30, 60, 90 and 120 min after challenge of guinea-pigs passively
sensitized to ovalbumin (OA) with aerosols of OA (2% in saline) (OA/OA,
n 4) saline (OA/SAL, n 4) or LPS (OA/LPS, n 1) and a control
serum treated animals challenged with LPS (CON/LPS, n ).
were incubated together; rabbit pre-immune
serum (5 #1) was without effect on the cytotoxicity.
(BAL at 90 min" OA/OA" + preimmune serum,
[TNF-0] 21 + 8 U/ml; + anti-TNF-0 serum,
[TNF-0] <2.0 U/rnl; OA/LPS" + preimmune
serum, [TNF-0q 71 ___
10 U/ml; + anti-TNF-0
serum, [TNF-0] < 2.0 U/ml.)
IL-I and IL-6: Neither IL-1 nor IL-6 could be
detected in BAL fluid as the latter was toxic to the
cell lines used to assay for the cytokines. Dialysis
of the BAL fluids for 24 h failed to completely
eliminate this toxicity.
Acute effects of inhalation of OA, safine and LPS aerosols in
guinea-pigs: In all guinea-pigs that were passively
sensitized to OA and inhaled OA aerosols, some
signs of anaphylaxis were noted despite the presence
of mepyramine. Animals were carefully observed
and those that showed signs of respiratory distress
were immediately removed from the exposure
chamber to prevent progression to severe respir-
atory distress and death. Exposure times in the
OA/OA groups ranged from 0.5 to 8 min. Mean
exposure time was 4.4-+-0.7 min (n 20). Dura-
tion of exposure to OA aerosol did not correlate
with the amount of TNF-0 detected in BAL fluid.
Discussion
We report the detection of TNF--like activity
in BAL fluid obtained from guinea-pigs passively
sensitized to OA and challenged with OA aerosols.
TNF-0-like activity could not be detected at 30 min
post-challenge, but it was measurable (8-26 U/ml)
in fluid obtained at 60, 90 and 120 min post
challenge. As rabbit anti-human TNF-0 antibodies
prevented the cytotoxicity of the lavage fluids, it is
highly likely that it is TNF-0. TNF- levels in BAL
fluids from animals that had inhaled LPS appeared
to peak about 90 min post-aerosol inhalation. It is
worth noting that these guinea-pigs inhaled LPS
aerosol for 40 min compared to OA aerosol for up
to 8 min in the other group. Thus, as we have not
defined the peak ofTNF- secretion into BAL fluid
for OA challenged animals, we cannot say whether
120 rain represents the maximal concentration that
may be achieved or whether its pattern of secretion
follows that seen after LPS inhalation. The levels
of TNF-0 detected in these experiments are similar
to those found by others in BAL fluid from
guinea-pigs after inhalation of LPS
13 or cotton
dust. 14
Unlike Broide et al.,
9 who measured ’resting’
TNF-0 levels in BAL fluid t’rom symptomatic and
asymptomatic asthmatics, but like Gosset et al.,
8 we
could not detect TNF- unless a protease inhibitor
was present in the lavaging solution. This is
noteworthy. All the passively sensitized guinea-pigs
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showed signs of anaphylaxis upon inhalation ofOA
aerosols, but the duration of exposure to the OA
aerosol did not appear to influence the amount of
TNF-0 detected in BAL fluid. Others14’1s have
shown that antigen challenge of sensitized animals
leads not only to the release of a variety of
mediators, but also to the release of proteases that
could metabolize cytokines such as TNF-0. Thus,
as BAL was performed 30-120 min after challenge,
lack of aprotinin in the lavaging solution could have
allowed metabolism of any TNF-0 released and thus
prevented its detection. This finding emphasizes the
importance of adding antiproteases to lavaging
solutions to help prevent breakdown of cytokines
during and after BAL.
Others6’7’17 have reported that IgE dependent
reactions result in TNF-0 formation and secretion.
In these experiments, the sensitizing antibody is
most likely to be a subtype of IgG, probably IgG1
or IgG2, as passive cutaneous anaphylaxis tests (data
not shown) revealed little or no IgE in the serum
used to passively sensitize animals. These findings
show that passive sensitization with anti-OA
antibodies of the IgG class followed by antigen
challenge can induce directly or indirectly the
synthesis and secretion of TNF-0. The production
of TNF-0 is not unique to a particular cell type, but
a major source of TNF-0 is macrophages.
2 Gosset
et a/. 8’17 showed that alveolar macrophages collected
from antigen challenged asthmatics undergoing a
late reaction generated significantly more TNF-
than similar patients who underwent only an early
reaction or who had experienced no reaction. We
speculate that, in our experiments in guinea-pigs,
most of the TNF-0 that is detectable is secreted
from alveolar macrophages. Neither IL-1 nor IL-6
could be detected as the lavage fluid was toxic to
the cell types used in the bioassay of these cytokines.
Preliminary experiments (data not shown) showed
that ELISAs for murine IL-1 and IL-6 could not
demonstrate the presence of these cytokines in BAL
fluid. Thus, whether these cytokines are present in
physiologically significant amounts in BAL fluid
remains to be determined.
The physiological significance of TNF-0 release
following passive sensitization and antigen chal-
lenge is unclear. Our data suggest that the release
of proteases and other mast cell associated
mediators during anaphylaxis may act to reduce
TNF-’s pro-inflammatory effects. Gosset et al.18
reported that human alveolar macrophages from
asthmatics have an enhanced capacity to produce
TNF-, compared with cells from normal control
subjects. Thus, TNF-0 may have a greater role in
the chronic inflammatory processes in asthma than
was previously supposed.
We conclude that TNF-0 is released in passively
sensitized guinea-pigs’ lungs soon after antigen
inhalation. A protease inhibitor must be present in
the lavaging solution to enable TNF-’s detection.
References
1. Brown PH, Crompton GK, Greening AP. Proinflammatory cytokines in
acute asthma. Lancet 1990; 338: 590-593.
2. Camussi G, Albano E, Tetra C, et al. The molecular action of tumor necrosis
factor-. Eur J Biochem 1991; 2(12: 3-14.
3. Schollmeier K. Immunologic and pathophysiologic role of tumor necrosis
factor. Am J Respir Cell Mol Biol 1991 3: 11--12.
4. Semenzato G. Tumour necrosis factor: cytokine with multiple biological
activities. Br J Cancer 1990; 61: 354-361.
5. Kings MA, Chapman I, Kristersson A, et al. Human recombinant
lymphokines and cytokines induce pulmonary eosinophilia in the guinea-pig
which is inhibited by ketotifen andAH 21-132. IntArch AllergyApplImmunol
1990; 91 354-361.
6. Ohno I, Ohkawara Y, Yamauchi K, et al. Production of tumor necrosis factor
with IgE receptor triggering from sensitized lung tissue. A J Respir Cell
Mol Biol 1991 3: 285-289.
7. Wershil BK, Wang Z-S, Gordon JR, et al. Recruitment of neutrophils during
IgE-dependent cutaneous late phase reactions in the is mast
cell-dependent. Partial inhibition of the reaction with antiserum against
tumor necrosis factor-alpha. J Clin Invest 1991; 87: 446-453.
8. Gosset P, Tsicopoulos A, Wallaert B, et al. Increased secretion of tumor
necrosis factor and interleukin-6 by alveolar macrophages consecutive to
the development of the late asthmatic reaction. J Allergy Clin Immuno! 1991;
88: 561-571.
9. Broide DH, Lotz M, Cuomo AJ, et al. Cytokines in symptomatic asthma
airways. J Allergy Clin Immunol 1992; 89: 958-967.
10. Hogan MM, Vogel SN. Measurement of tumor necrosis factor 0 and ft. In:
Coligan E, Kruisbeek AM, Marguiles DH, et al. eds. Current Protocols in
Immunology. New York: John Wiley & Sons, 1991; 6.10.1-6.10.3.
11. Nordan RP. Measurement of and human interleukin 6. In: Coligan
E, Kruisbeek AM, Marguiles DH, et al. eds. Current Protocols in Immunology.
New York: John Wiley & Sons, 1991; 6.10.1-6.10.3.
12. Muegge K, Durum SK. Measurement of soluble and membrane-bound
interleukin-1. In: Coligan E, Kruisbeek AM, Marguiles DH, et al. eds. Current
Protocols in Immunology. New York: John Wiley & Sons, 1992; 6.2.1-6.2.4.
13. De Rochemontieux-Galve B, Marchat-Amoruso B, Dayer J-M, et al. Tumor
necrosis factor and interleukin-1 activities in free lung cells after single and
repeated inhalation of bacterial endotoxin. Infect Immunity 1991; 59:
3646-3650.
14. Ryan LK, Karol MH. Release of tumor necrosis factor in guinea-pigs after
inhalation of cotton dust. A J Respir Cell Mol Biol 1991 5: 93-98.
15. Miller HRP, Woodbury RG, Huntley JF, et al. Systemic release of mucosal
mast-cell protease in primed rats challenged with Nippostrongylus brasiliensis.
Immunology 1983; 49: 471-479.
16. Caughey GH, Lazarus SC, Viro NF, et al. Tryptase and chymase: comparison
of extraction and release in two dog mastocytoma lines. Immunology 1988;
63: 339-344.
17. Borish L, Mascali j, Rosenwasser LJ. IgE-dependent cytokine production
by human peripheral blood mononuclear phagocytes. J Immunol 1991; 147:
63-67.
18. Gosset P, Tsicopoulos A, Wallaert B, et al. Tumor necrosis factor alpha and
interleukin-6 production by human mononuclear phagocytes from allergic
asthmatics after IgE-dependent stimulation. Am Rev Respir Dis 1992; 146:
768-774.
ACKNOWLEDGEMENTS. This work supported by the Medical Research
Council of Canada, the Alberta Lung Association, the Natural Sciences and
Engineering Research Council of Canada, the Fond de Recherche Sant&
du Quebec and the Association Pulmonaire du Qu+bec. D.K. thanks the
Alb.erta Lung Association for Graduate Scholarship. We thank Marie B+dard
for processing the data and for the statistical analyses.
Received 2 September 1992"
accepted in revised form 5 October 1992
428 Mediators of Inflammation. Vol 1992